Study suggests two doses of COVID-19 vaccine may offer some protection for kidney transplant patients

By Susha Cheriyedath, M.Sc.Sep 27 2021

Studies show that in transplant recipients, the humoral response to two doses of a COVID-19 vaccine is inferior to that in immunocompetent individuals. However, there is not much data on the real-world efficacy of COVID-19 vaccination in kidney transplant recipients.

Study: Real-world Effectiveness of 2-dose SARS-CoV-2 Vaccination in Kidney Transplant Recipients. Image Credit: Hospital man / Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Studying the impact of COVID-19 vaccination on SARS-CoV-2 infection and outcomes in kidney transplant patients

Researchers from Toronto, Canada, performed a cohort study to analyze the impact of COVID-19 vaccination on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in kidney transplant patients. This study is available on the preprint server, medRxiv.*

They recorded the COVID-19 vaccination and infection status of all patients in their transplant program between March 11, 2020, and July 19, 2021, along with demographic factors and clinical covariates related to the severity of disease.

They used a time-varying Cox-proportional hazards model to examine the association between vaccination status and SARS-CoV-2 infection risk after adjusting for sex, age, time post-transplant, COVID-predisposing comorbidities, kidney function, and the weekly infection rate in each patient’s community. The secondary outcome of the study was severe SARS-CoV-2 infection defined as COVID-related hospital admission or death.

Out of 1,793 kidney transplant recipients evaluated, 1,540 (85.9%) recipients had received one dose of the vaccine, and 1,402 (78.2%) had received two vaccine doses by the end of the study. The median age was 60.4 years and the median time after transplantation was 8.1 years.

Association between community infection rates and transplant duration <3 months and risk of infection

Out of the 114 SARS-CoV-2 infections, 61% were severe. Community infection rates and transplant duration of less than 3 months were associated with the risk of infection. They observed similar associations for severe SARS-CoV-2 infections when compared to unvaccinated patients. No association between two doses of vaccination and any SARS-CoV-2 infection or severe SARS-CoV-2 infection was observed.

They conducted a sensitivity analysis to study the impact of administration of any vaccine dose on any SARS-CoV-2 infection and severe infection and the results showed no change in overall effect.

According to the authors, although this vaccination effectiveness analysis is limited by cohort size, the results clearly show that the infection and poor outcome risks were predominantly determined by transplant vintage and community infection rates and not by vaccination status.

More recent studies have demonstrated that a 3^rd dose of the COVID-19 vaccine offers greater immunogenicity in transplant recipients.

“Future studies must examine whether such strategies enhance real-world vaccine effectiveness among transplant patients.”

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources